Stock Analysis
Exelixis IncEXEL
P/E 17.92×· 5Y range 13.99–84.98×· 27th percentile of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsHold27 analystsP/E 17.9× sits at the 27th percentile of its 5.062286105407256-year history.
PMP Verdict
High quality, fairly valued
Strengths
- Profitability100
- Growth90
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Altman Z 17.8 — safe-zone balance sheet
- ✓ROE 39.8% — efficient capital deployment
- ✓Revenue CAGR 12.8% — durable top-line growth
- ✓Interest coverage 327253.0× — debt well covered
What's happening with EXEL
Profile
Strong profitability, growth and financial health.
How is each axis scored?
- Valuation62/100 · Moderate
- P/E vs own history (27th pct)20/25
- FCF yield (7.5%)20/25
- P/S (6.4x)12/25
- EV/EBIT (n/a)10/25
- Growth90/100 · Strong
- Revenue CAGR (12.8%)20/25
- Net income CAGR (35.7%)25/25
- EPS CAGR 5Y (40.3%)25/25
- Fwd implied growth (16.3%)20/25
- Profitability100/100 · Strong
- ROIC (69.6%)25/25
- ROE (39.8%)25/25
- Net margin (35.3%)25/25
- Operating margin (39.9%)25/25
- Financial Health75/100 · Strong
- Altman Z (17.84)25/25
- Current ratio (3.56)25/25
- Interest coverage (327253.0x)25/25
- Net cash / debt (n/a)0/25
- Quality65/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-2.64)25/25
- FCF conversion (136%)25/25
- Margin stability (σ 61.0%)0/25
- Moat70/100 · Moderate
- ROIC >12% years (7/8 yrs)20/25
- Median gross margin (96.4%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -36.7%)0/25
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Show more
Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Headquarters: ALAMEDA, CA · Employees: 1,077 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
62BP/E (TTM)18.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 14.0x–85.0x · 27th pct
P/FCF13.3xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.5%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.2%–9.4% · 90th pct
P/S (TTM)6.42xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.0x–6.4x · highest in history
EV/EBITDA15.3xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales6.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio7.23xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.19B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC69.6%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE39.8%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA32.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin35.3%A
Grade A: HighNet Income / Revenue
Operating Margin39.9%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin96.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin48.1%A
Grade A: HighFCF / Revenue
True FCF Margin43.5%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
90A+Revenue CAGR12.8%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR35.7%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)40.3%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth16.3%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-23.1%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income13.1%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.6%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score17.84A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.56xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.21xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage327253.0xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
65BPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.64A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion136.2%A
Grade A: StrongFCF / Net Income
Margin Stability61.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.5%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.91xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Beckerle Mary C Filed | Beckerle Mary C | SellOpen market sale | -9812 | |
Eckhardt Sue Gail Filed | Eckhardt Sue Gail | SellOpen market sale | -9812 | |
WYSZOMIERSKI JACK L Filed | WYSZOMIERSKI JACK L | SellOpen market sale | -3925 | |
Eckhardt Sue Gail Filed | Eckhardt Sue Gail | Grant / award | +8.4K | |
Heyman Tomas J. Filed | Heyman Tomas J. | Grant / award | +8.4K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Caligan Partners LP Filed | Caligan Partners LP | Grant / award | +19.1K | |
Oliver Bob Filed | Oliver Bob | Grant / award | +8.4K | |
Smith Julie Filed | Smith Julie | Grant / award | +8.4K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
70B+ROIC >12% Years7/8 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)96.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-36.7%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.47
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.37
Cash & short-term investments per share (Finnhub)
Book Value / Share$7.41
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.06B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.16B
Shareholders' equity (book value)
Asset / Liability4.16xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$15.63B
Current Market Capitalization
Beta0.44B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jul 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Exelixis Inc (EXEL)
EXEL is down 0.95% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Exelixis Inc. Altman Z-Score of 17.84 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.64 suggests a low likelihood of earnings manipulation.
- Exelixis Inc converts about 48% of revenue into free cash flow — strong cash generation.
- Exelixis Inc posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- Return on equity of 39.8% is well above the market average.
See how EXEL ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all EXEL moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 62.67 | +2.75% | 2.01 |
| Oct 15 | After-hours | 63.00 | +3.30% | 2.44 |
Frequently Asked Questions about EXEL
What is the current Exelixis Inc (EXEL) stock price?
EXEL is trading at $62.23 at the last market close, down 0.95% on the session. PreMarketPrice tracks EXEL pre-market, intraday and after-hours prices.
Is EXEL stock a buy right now?
PreMarketPrice's quantitative model rates Exelixis Inc's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is EXEL stock overvalued?
Exelixis Inc trades at a trailing P/E of 18.2 and our valuation score rates it 62/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Exelixis Inc report earnings?
No confirmed earnings date is currently scheduled for EXEL. The Earnings section lists recent reports and updates as dates are announced.
What sector does Exelixis Inc operate in?
Exelixis Inc operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Exelixis Inc do?
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer.
About Exelixis Inc (EXEL) Stock
Exelixis Inc (EXEL) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Exelixis Inc is trading at $62.23, down 0.95% on the day with a market capitalization of $15.6 billion. The financial health score for EXEL is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for EXEL stock.
EXEL Stock Analysis & Key Metrics
On PreMarketPrice, you can track Exelixis Inc (EXEL) across multiple dimensions:
- Pre-market price & movement: Real-time EXEL stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for EXEL with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Exelixis Inc across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for EXEL.
- Sector peers: Compare EXEL against 5 other healthcare stocks on key financial metrics.
Is EXEL a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Exelixis Inc (EXEL) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Exelixis Inc (EXEL) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.